Pantoprazol Terapia (Pantoprazole Sodium Sesquihydrate)

Pantoprazol Terapia is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates healing of erosions caused by chronic acid exposure.
• Peptic ulcer disease: supports ulcer healing and reduces the risk of recurrence.
• Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with this rare endocrine disorder.

• Pantoprazole selectively inhibits the H+/K+‑ATPase enzyme (the gastric proton pump) located on the secretory surface of parietal cells. By binding covalently to the pump’s cysteine residues, it blocks the final step of acid production, leading to a sustained increase in gastric pH and reduced acidity in the stomach.

Pantoprazol Terapia may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: increased intestinal gas.
• Constipation: infrequent.

Serious or Rare Side Effects

• Severe allergic reaction (anaphylaxis): skin rash, swelling, breathing difficulty.
• Clostridioides difficile infection: persistent watery diarrhoea.
• Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat.
• Bone fractures: increased risk with long‑term use.
• Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.
• Liver enzyme elevation: abnormal liver function tests.

When prescribing Pantoprazol Terapia, clinicians should consider several safety aspects:

• Renal impairment: dose adjustment may be required in severe kidney disease.
• Hepatic impairment: monitor liver function in patients with moderate to severe liver disease.
• Long‑term therapy: assess need for continued use to minimise fracture risk.
• Drug interactions: review concomitant medications that may affect gastric pH or metabolism.
• Pregnancy and lactation: use only if the potential benefit justifies the potential risk.

Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Pantoprazol Terapia can affect the absorption and metabolism of several co‑administered drugs.

Major Interactions (Avoid)

• Clopidogrel: reduced antiplatelet effect may increase cardiovascular risk.
• Atazanavir and other protease inhibitors: decreased absorption due to higher gastric pH.

Moderate Interactions (Monitor Closely)

• Warfarin: possible alteration of INR; monitor coagulation parameters.
• Methotrexate: reduced clearance may raise toxicity risk.
• Digoxin: increased serum concentrations; check levels periodically.
• Iron supplements: diminished absorption; separate dosing by at least 2 hours.